Biotech stocks are emerging from a four-year slump ... co-manager of the Harbor Health Care ETF MEDI. 5. Tariff risks are easing: To minimize tariff risks, big pharma companies are setting up ...
The Vanguard FTSE Developed Markets ETF tracks the FTSE Developed All Cap ex U.S. index. The SPDR Portfolio Developed World ex-US ETF tracks the S&P Developed Ex-U.S. BMI index. Despite tracking ...
Zacks Investment Research on MSN
Biotech ETFs Hovering Around a 52-Week: Here's Why
Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB has rallied 26.1% over the past six months (as of Oct. 27, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 24.4%). Year to ...
Stocks to Buy and Sell. Biotechnology ETF (NASDAQ:IBB) is one of the trending analyst calls. Jason Snipe, Founder and CIO of ...
On the sell side, ARK trimmed its holdings in several companies, with the most notable sale being 61,072 shares of SHOPIFY INC (NYSE:SHOP), valued at $10,691,264. This followed a pattern of reducing ...
Zacks Investment Research on MSN
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
Making its debut on 06/19/2006, smart beta exchange traded fund First Trust NYSE Arca Biotechnology ETF (FBT) provides investors broad exposure to the Health Care ETFs category of the market. What Are ...
Another major investment by ARK was the acquisition of 385,585 shares of Block Inc (NYSE:XYZ), a financial services and mobile payment company formerly known as Square, with a total value of ...
The buyout of one biotechnology company can sometimes hurt the shares of its competitors, as investors may feel like they picked the wrong merger candidate. But not in the case for those who bought ...
Biopharma has finally begun catching up with the overall stock market, as shares of the top three biopharma exchange traded funds (ETFs) jumped well into double digits over the past six months.
BIB ETF is best suited for high-risk, active investors in the accumulation phase or retirees managing portfolios hands-on.
Something unusual is happening to biotech stocks: They’re going up. A drug-pricing deal between Pfizer and the White House and a spate of deals have sent the SPDR S&P Biotech exchange-traded fund up 9 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results